Nuvalent (NUVL) Share-based Compensation (2020 - 2026)
Nuvalent's (NUVL) quarterly Share-based Compensation came in at $226.2 million in Q1 2026, up 28245.86% YoY from N/an in Q1 2025, and up 940.77% on a QoQ basis from $21.7 million in Q4 2025.
Nuvalent (NUVL) Share-based Compensation (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Share-based Compensation data on file, last reported at $226.2 million in Q1 2026.
- Quarterly Share-based Compensation rose 28245.86% year-over-year to $226.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226.2 million (up 1832.14% YoY) and the FY2025 annual result came in at $170.4 million, up 17.92% from the prior year.
- Share-based Compensation rose to $226.2 million in Q1 2026, from $21.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $226.2 million in Q1 2026 to a low of -$44.4 million in Q4 2024.
- A 5-year average of $19.4 million and a median of $6.9 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation tumbled 693.34% — and 2026, when it surged 28245.86%.
- Tracing NUVL's Share-based Compensation over 5 years: stood at $3.0 million in 2022, then surged by 148.26% to $7.5 million in 2023, then plunged by 693.34% to -$44.4 million in 2024, then surged by 148.91% to $21.7 million in 2025, then surged by 940.77% to $226.2 million in 2026.
- The last three Share-based Compensation figures came in at $226.2 million (Q1 2026), $21.7 million (Q4 2025), and $22.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 226.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 226.20 Mn |
| Mar 31, 2026 | 226.20 Mn |
| Dec 31, 2025 | 21.73 Mn |
| Dec 31, 2025 | 21.73 Mn |
| Sep 30, 2025 | 22.31 Mn |
| Sep 30, 2025 | 22.31 Mn |
| Jun 30, 2025 | 22.07 Mn |
| Jun 30, 2025 | 22.07 Mn |
| Mar 31, 2025 | 798,000.00 |
| Mar 31, 2025 | 798,000.00 |
| Dec 31, 2024 | -44.44 Mn |
| Dec 31, 2024 | -44.44 Mn |
| Sep 30, 2024 | 15.46 Mn |
| Sep 30, 2024 | 15.46 Mn |
| Jun 30, 2024 | 15.13 Mn |
| Jun 30, 2024 | 15.13 Mn |
| Mar 31, 2024 | 13.86 Mn |
| Mar 31, 2024 | 13.86 Mn |
| Dec 31, 2023 | 7.49 Mn |
| Dec 31, 2023 | 7.49 Mn |